Matinas Biopharma (NYSEAMERICAN:MTNB) Trading 0.4% Higher – Still a Buy?

Posted by Amy Steele on Aug 16th, 2026

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report)’s share price was up 0.4% during mid-day trading on Friday . The stock traded as high as $0.25 and last traded at $0.2340. Approximately 2,402,845 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 14,997,717 shares. The stock had previously closed at $0.2330.

Matinas Biopharma Stock Performance

The firm has a market capitalization of $1.50 million, a P/E ratio of -0.20 and a beta of 1.76. The stock’s 50 day simple moving average is $0.49 and its 200 day simple moving average is $0.57.

Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.